false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP08.01. Lymphocyte Count Pre-immunotherapy Predic ...
EP08.01. Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy - PDF(Slides)
Back to course
Pdf Summary
This study aimed to investigate the correlation between peripheral blood lymphocyte counts at different time points and clinical outcomes in Stage III non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) and durvalumab. The researchers tracked lymphocyte counts at pre-CCRT, nadir during CCRT, and before cycle 1 of durvalumab. The results showed that patients who received durvalumab had improved progression-free survival (PFS) and overall survival (OS) compared to those who did not receive durvalumab. Higher pre-durvalumab lymphocyte counts were significantly linked to better PFS in patients treated with durvalumab. However, no significant association was found between PFS or OS and pre-CCRT or nadir lymphocyte counts. <br /><br />In conclusion, the study observed improved PFS and OS in Stage III NSCLC patients treated with CCRT and durvalumab consolidation. The circulating lymphocyte counts before receiving durvalumab were found to predict PFS benefit in this patient group. The results highlight the importance of incorporating peripheral blood lymphocyte counts as a potential biomarker in predicting treatment efficacy in Stage III NSCLC patients. Further research is needed to validate these findings and to explore other potential biomarkers for treatment response in this patient population.
Asset Subtitle
Ashley Horne
Meta Tag
Speaker
Ashley Horne
Topic
Local-Regional NSCLC: Biomarkers
Keywords
correlation
peripheral blood lymphocyte counts
time points
clinical outcomes
Stage III non-small cell lung cancer
NSCLC
chemoradiotherapy
durvalumab
progression-free survival
overall survival
×
Please select your language
1
English